Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential ankyrin 1 (TRPA1) and transient receptor potential vanilloid 1 (TRPV1) are non-selective cation channels primarily expressed in nociceptive sensory neurons (Julius, 2013). They serve as polymodal sensors for noxious heat (TRPV1), cold (TRPA1), and various chemical irritants, and are known to be co-expressed and form functional heteromeric complexes (Starowicz et al., 2008; Akopian, 2011). These channels play a significant role in chronic pain, neurogenic inflammation, and respiratory conditions like asthma and chronic cough (Nilius & Szallasi, 2014). Therapeutic targeting of these channels, particularly through antagonism, aims to alleviate pain and inflammation, though clinical progress for TRPV1 antagonists has been hindered by side effects such as hyperthermia (Gavva et al., 2008). The interaction between TRPA1 and TRPV1 suggests that dual antagonism or targeting the heteromeric complex may offer enhanced therapeutic efficacy in certain disease states.
Antagonism of TRPA1 and TRPV1 ion channels to inhibit the influx of cations (Ca2+, Na+), thereby reducing neuronal excitability and pain signaling (Julius, 2013; Nilius & Szallasi, 2014).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1 (TRPA1/TRPV1).